WST-057
Peripheral Neuropathy (Diabetic, Chemo-Induced, HIV-Induced)
Phase 3Active
Key Facts
Indication
Peripheral Neuropathy (Diabetic, Chemo-Induced, HIV-Induced)
Phase
Phase 3
Status
Active
Company
About WinSanTor
WinSanTor is pioneering a potentially first-in-class, nerve-regenerating topical treatment for peripheral neuropathies, a large and underserved market. Its lead candidate, WST-057, has generated promising Phase 2a data published in eBioMedicine (The Lancet) and is now in Phase 3 development. The company is privately held and has been primarily funded by over $40 million in non-dilutive grants from U.S. and Canadian government agencies. With a leadership team and founding KOLs possessing deep expertise in neuropathy, WinSanTor aims to deliver the first disease-modifying therapy for millions of patients.
View full company profile